Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No More Mr. NICE Guy: Pfizer/Eisai Seek Court Review Of Cost-Effectiveness Appraisal For Alzheimer’s Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Judicial review of U.K. appraisal limiting acetylcholinesterase inhibitors to moderately severe Alzheimer’s would mark the first time NICE has been challenged at that level, firms say.

You may also be interested in...



Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal

Grounds for review include procedural issues, irrationality and human rights, according to Eisai.

Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal

Grounds for review include procedural issues, irrationality and human rights, according to Eisai.

NICE To Release Final Alzheimer's Guidance Nov. 22

Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel